FDA approves Sanofi's Subcutaneous Sarclisa?

Summary

The market prices YES at 88.5%, up 21.5 points in the last 24 hours on $3K of daily volume. Over the charted period the probability has ranged between 31.0% and 88.5%, trending upward by 38.5 points overall. Liquidity of $6K makes this a thinner market — treat the printed probability with some caution.

AI insight

This is a quantitative read derived from live Polymarket data only — no AI or news research was performed. Connect Ollama for local open-model analysis, or a hosted AI key for web-grounded research. Structurally: liquidity is thin, so the printed probability can move sharply on small orders, and the 21.5-point 24h move suggests new information is being priced in right now — check the news before trading.

Deterministic analysis from live Polymarket data only. Connect Ollama or a hosted AI key for generated reasoning.

Timeline

1. Jul 1

   Charted period opens at 50.0%

   Start of the available price history window.

2. Jul 3

   Period high: 88.5%

   Peak market-implied probability of YES.

Resolution rules

As of market creation, the FDA's expected decision date for the specified application is July 23, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Sanofi's Subcutaneous Sarclisa in combination with approved standard-of-care regimens for the treatment of multiple myeloma across currently approved Sarclisa IV indications by August 6, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.

Sources